In 80.3% of the patients, tumor specimens originating from the same location (endoscopic biopsy of the primary tumor, or resection specimen, or biopsy from metastases) were tested for HER2 in both the central and local pathology laboratories (comparable cases, n = 390). The gene discussed is ERBB2; the disease is neoplasm.